izalontamab brengitecan + serplulimab

BL-B01D1 + serplulimab is an investigational combination regimen consisting of izalontamab brengitecan (BL-B01D1, BMS-986507), a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, and serplulimab (HLX10), an anti-PD-1 monoclonal antibody. Izalontamab brengitecan consists of a humanized bispecific antibody targeting EGFR and HER3 conjugated to a novel topoisomerase I inhibitor payload (Ed-04) via a cleavable tetrapeptide-based linker. Serplulimab is a humanized IgG4 monoclonal antibody that blocks the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby reactivating T-cell-mediated antitumor immune responses. The combination is designed to leverage the synergistic effects of ADC-induced immunogenic cell death and immune checkpoint inhibition. It is being developed primarily for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and other advanced solid tumors.

Other names

BL-B01D1 + serplulimabBL-B01D1 plus serplulimabBL-B-01D1 plus serplulimabBL-B 01D1 plus serplulimabBMS-986507 + serplulimabBMS-986507 plus serplulimabBMS986507 plus serplulimabBMS 986507 plus serplulimabiza-bren + serplulimabiza-bren plus serplulimabizalontamab brengitecan + serplulimabizalontamab brengitecan and serplulimabizalontamab brengitecan plus serplulimabserplulimab + BL-B01D1serplulimab + BMS-986507serplulimab + iza-brenserplulimab + izalontamab brengitecan